Seoul Economic Daily EnglishQwen · 实盘不做把握 7/10不做原因:已被定价
北京时间·🕒 发布 16:16:27(首尔 17:16)·⟳ 抓取 16:26:33 +10m06s·⚡ 决策 09-01 16:28:13 +1m40s·56.1 天前
부광약품子公司Union Korea Pharm法院回生程序正式终结
Bukwang Pharmaceutical(003000.KS)今日已因该消息放量上涨+4.66%(量比17.31倍),盘中最高触及4875韩元(+16.5%)后大幅回落至4380韩元收盘,呈明确的高位派发形态。事件本身为程序性确认(8月14日已申请终结、债务已基本清偿),投资行为发生在3个月前(5月27日),市场有充分时间消化。韩股已收盘,次日开盘追高无正期望。
📄 原文Seoul Economic Daily English↗ 原文
Bukwang Unit Union Korea Pharm Exits Court Rehabilitation
Court rehabilitation proceedings for Union Korea Pharm, a subsidiary of Bukwang Pharmaceutical, have formally concluded…
不做 Bukwang Pharmaceutical（003000.KS）
股价今日已因该消息放量+4.66%(量比17.31x),盘中冲高至+16.5%后大幅回落,呈典型派发/见光死形态。事件为程序性里程碑(8月14日已申请、债务已清偿),投资发生在3个月前,市场已充分定价。韩股已收盘,次日追高无正期望。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Bukwang子公司回生程序终结是正面但程序性的里程碑事件。投资发生于5月27日,回生终结申请于8月14日提交,债务清偿已基本完成——市场对此有充分预期。今日(9月1日)股价已放量+4.66%(量比17.31x)反应,且盘中从+16.5%高点大幅回落,显示获利盘派发。韩股已收盘,次日追高面临见光死风险,无正期望edge。
🔎 新鲜度:最早出现 2026-09-01 · 扩散 medium · price-in 风险 high ↗
主要风险
- 今日盘中从+16.5%高点回落至+4.66%收盘,次日存在继续回落/见光死风险
反向证据
- 做多前查反向 · 来源 stock_quote · 日期 2026-09-01 · 影响 weakens
今日量比17.31x+盘中从4875回落至4380,显示大量获利了结;52周高点9890,当前距高-55.7%,长期趋势偏弱
检索:Bukwang Pharmaceutical 003000 recent news risk
先例如何影响了这次决策
对本次决策的影响:先例不足不改变结论——价格已充分反应是独立于先例的AVOID依据
方向:无足够先例
涨幅量级:无同市场同机制先例可供校准
形态:今日盘中已呈现冲高回落形态,与'见光死'模式一致
工具执行结果 · 成功 1 · 降级 1 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 936 ms
{"result": "search_processed_events:agent query=`003000 회생종결 | bukwang pharmaceutical union korea pharm rehabilitation terminated | 부광약품 연합약품 회생절차 종결`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 70.8/72 小时、1651 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重复；按当前事件继续正常研判。"} - stock_quote 降级 stock_tools HTTP · 4,911 ms
{
原文全文
展开原文 · 2,034 字
Court rehabilitation proceedings for Union Korea Pharm, a subsidiary of Bukwang Pharmaceutical, have formally concluded.
Bukwang Pharmaceutical (003000) said on the 1st that the Seoul Rehabilitation Court decided on the 31st to terminate the rehabilitation proceedings for Union Korea Pharm under the Debtor Rehabilitation and Bankruptcy Act.
Bukwang Pharmaceutical had paid a total of 30 billion won ($21.6 million) for new shares on May 27, becoming the largest shareholder of Union Korea Pharm. Union Korea Pharm subsequently carried out changes to creditor rights and repayment of rehabilitation claims under its rehabilitation plan. Of about 29.2 billion won in claims due for repayment this year, the company repaid most of the total, excluding some unconfirmed claims. The remaining unpaid balance stands at 76 million won. The company filed for termination of the rehabilitation proceedings with the Seoul Rehabilitation Court on the 14th of last month.
Union Korea Pharm's financial structure has improved significantly since the acquisition. According to Bukwang Pharmaceutical, the company's debt-to-equity ratio has fallen to the 40% range from a state of impaired capital before the acquisition. Past unpaid trade payables, borrowings and bonds with warrants have all been repaid, the company said.
Cooperation between the two companies has already begun. Bukwang Pharmaceutical outsourced drug production to Union Korea Pharm and shipped the digestive medicine Bokhap Pazyme Double Tablet in June. Hardcal Chewable Tablet and Hardcal Chewable Easy Tablet, over-the-counter thyroid and endocrine drugs, will also be produced at Union Korea Pharm and shipped starting this month.
"Only some normal claims such as trade payables and return provisions remain, so the effective debt-to-equity ratio is about 15%," an official at Bukwang Pharmaceutical said. "We will maximize sales and manufacturing synergies between the two companies to expand both companies' top line and work toward turning Union Korea Pharm profitable."
Bukwang Pharmaceutical (003000) said on the 1st that the Seoul Rehabilitation Court decided on the 31st to terminate the rehabilitation proceedings for Union Korea Pharm under the Debtor Rehabilitation and Bankruptcy Act.
Bukwang Pharmaceutical had paid a total of 30 billion won ($21.6 million) for new shares on May 27, becoming the largest shareholder of Union Korea Pharm. Union Korea Pharm subsequently carried out changes to creditor rights and repayment of rehabilitation claims under its rehabilitation plan. Of about 29.2 billion won in claims due for repayment this year, the company repaid most of the total, excluding some unconfirmed claims. The remaining unpaid balance stands at 76 million won. The company filed for termination of the rehabilitation proceedings with the Seoul Rehabilitation Court on the 14th of last month.
Union Korea Pharm's financial structure has improved significantly since the acquisition. According to Bukwang Pharmaceutical, the company's debt-to-equity ratio has fallen to the 40% range from a state of impaired capital before the acquisition. Past unpaid trade payables, borrowings and bonds with warrants have all been repaid, the company said.
Cooperation between the two companies has already begun. Bukwang Pharmaceutical outsourced drug production to Union Korea Pharm and shipped the digestive medicine Bokhap Pazyme Double Tablet in June. Hardcal Chewable Tablet and Hardcal Chewable Easy Tablet, over-the-counter thyroid and endocrine drugs, will also be produced at Union Korea Pharm and shipped starting this month.
"Only some normal claims such as trade payables and return provisions remain, so the effective debt-to-equity ratio is about 15%," an official at Bukwang Pharmaceutical said. "We will maximize sales and manufacturing synergies between the two companies to expand both companies' top line and work toward turning Union Korea Pharm profitable."
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。